Gujarat Terce Lab Peer Comparison

BSE: 524314

₹37.62

₹0.71 (1.92%)

As on 26-Aug-2026IST

Market cap

₹29 Cr

Revenue (TTM)

₹46 Cr

P/E Ratio

14

P/B Ratio

3.1

Div. Yield

0 %

Edit

	Gujarat Terce Lab	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Market cap (₹ Cr)	29	21,951	19,147	17,889	18,136
Revenue (₹ Cr)	46	2,570	2,287	2,432	3,230
Net Profit (₹ Cr)	2.09	735.15	678.07	169.62	666.92
Net Margin (%)	4.51	26.88	28.10	6.90	20.60
RoE (%)	26.36	19.16	19.73	20.76	18.75
Price to Earnings	14.02	29.86	28.78	105.46	28.17
Price-To-Book	3.07	4.98	5.08	19.78	4.48

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Gujarat Terce Lab	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Operating Revenue	47.47	2,519.65	1,937.47	2,275.58	2,893.64
Total Income	47.81	2,707.60	2,033.90	2,304.07	2,912.00
Total Expenditure	43.72	1,615.47	1,290.54	2,013.55	1,876.44
EBITDA	3.75	904.18	646.93	262.03	1,017.20
Depreciation	0.42	57.73	65.96	28.58	315.46
EBIT	3.33	846.45	580.97	233.45	701.74
Interest	0.18	9.57	0.61	4.49	231.29
Other Income	0.34	187.95	96.43	28.49	18.36
Exceptional Items	-0.45	-49.16	--	-5.25	--
Profit before Tax	3.03	975.67	676.78	252.20	488.87
Provision for Tax	0.83	253.24	135.69	64.68	114.20
Profit after Tax	2.20	722.43	541.09	187.52	374.67

Liabilities (₹ Cr)

	Gujarat Terce Lab	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Shareholder's Funds	9.73	4,202.90	2,850.49	872.79	2,854.36
Minority Interest	--	--	35.90	--	417.40
Non-Current Liabilities	3.17	19.19	13.24	394.49	2,100.97
Current Liabilities	10.95	627.48	305.99	1,109.50	1,489.55
Total Liabilities	24.55	4,921.88	3,207.85	2,414.58	6,862.28

Assets (₹ Cr)

	Gujarat Terce Lab	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Non-Current Assets	9.44	1,046.35	1,071.67	509.16	5,531.13
Current Assets	14.41	3,803.22	2,133.95	1,859.88	1,331.15
Total Assets	24.55	4,921.88	3,207.85	2,414.58	6,862.28
Total Debt*	1.30	2.50	0.55	0.00	2,421.66
Net Current Assets	3.46	3,175.74	1,827.96	750.38	-158.40
Contingent Liabilities	--	370.49	0.64	121.23	64.29

Cashflow (₹ Cr)

	Gujarat Terce Lab	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Cash From Operating Activities	1.71	967.57	432.37	-15.14	1,065.01
Cash Flow from Investing Activities	-0.11	-561.67	-334.73	18.69	-79.97
Cash from Financing Activities	0.47	-798.31	-38.32	-91.97	-881.32
Net Cash Inflow / Outflow	2.08	-392.41	59.32	-88.42	103.72

Ratios

Profitability Ratios

	Gujarat Terce Lab	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
ROCE (%)	34.83	23.39	26.22	31.24	13.59
ROE (%)	27.77	17.16	21.72	23.02	13.81
ROA (%)	9.52	14.91	18.37	8.90	5.48
EBIT Margin (%)	8.61	43.34	38.37	12.77	35.79
Net Margin (%)	4.60	26.68	26.60	8.14	12.87
Cash Profit Margin (%)	5.53	29.72	31.33	9.47	23.22

Growth Ratios

	Gujarat Terce Lab	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Revenue Growth (%)	-5.42	10.45	14.37	32.59	44.02
EBIT Growth (%)	-2.43	19.68	20.21	-1.38	48.22
Net Profit Growth (%)	324.98	-5.88	17.27	62.02	-5.65
EPS Growth (%)	314.27	-5.88	17.25	62.02	-10.39
Book Value Growth (%)	58.76	-0.34	23.77	13.51	10.19

Valuation Ratios

	Gujarat Terce Lab	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Price / Earnings	10.94	29.89	28.38	103.45	54.83
Price / Book Value	2.47	5.14	5.52	22.39	6.78
Dividend Yield (%)	0.00	1.59	0.30	0.46	0.52
EV/EBITDA	5.51	16.93	19.78	65.23	20.75
Market Cap (₹ Cr)	24.07	21,592.90	15,219.80	19,398.64	19,292.77

Solvency Ratios

	Gujarat Terce Lab	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Debt to Equity	0.13	0.00	0.00	0.00	0.85
Short term debt to equity ratio	0.12	0.00	0.00	--	0.14
Current Ratio	1.32	6.06	6.97	1.68	0.89
Quick Ratio	0.98	5.31	5.88	0.75	0.67
Interest Coverage	17.89	102.95	1,110.48	57.17	3.11

Operating Efficiency Ratios

	Gujarat Terce Lab	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Debtors to sales (%)	10.25	7.22	32.65	9.39	15.85
Asset Turnover	2.05	0.54	0.66	1.08	0.43
Receivable days	38.19	26.06	110.70	31.88	54.07
Inventory Days	28.46	65.95	65.86	126.03	32.16
Payable days	57.97	81.01	105.88	163.79	140.91
Cash Conversion Cycle	8.69	11.00	70.68	-5.88	-54.68

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.